Target the complement Factor B pathway¹

FABHALTA is the first and only complement Factor B inhibitor proven to slow kidney function decline in IgAN

FABHALTA binds to Factor B of the alternative complement pathway

FABHALTA significantly slowed eGFR decline over 24 months vs placebo

• The annualized mean change from baseline in eGFR (mL/min/1.73 m²) estimated over 24 months was -3.0 per year for FABHALTA and -5.7 per year for placebo (treatment effect: 2.8 per year [95% CI: 1.6, 3.9; P<0.0001])

The most common adverse reactions (≥5%) in adults with IgAN receiving FABHALTA
were abdominal pain and dizziness

Take targeted action with FABHALTA for your adult patients with IgAN at risk of disease progression

Broad and established coverage enable access to FABHALTA

• 96% of IgAN patients paid $10 or less per month*

The information provided is not a guarantee of coverage. Actual benefits are determined by each plan administrator in accordance with its policies and procedures. Because formularies change and many health plans offer more than one formulary, please check with the health plan to confirm coverage for individual patients.[PARAGRAPH BREAK]*Specialty pharmacy data from April 2025 to March 2026 for 3019 prescribers, which represents approximately 99% of total prescriptions. For remaining people, the out-of-pocket cost for the product varies and may be as high as the total cost of the product.